lx2-32c

**LX2-32c** is a novel, semi-synthetic taxane derivative generated from cephalomannine. It exhibits strong antitumor activity against several cancer cell lines, including paclitaxel-resistant tumors. Its mechanism is similar to other taxanes like paclitaxel and docetaxel: it promotes tubulin polymerization, stabilizing microtubules and thereby inhibiting cell division. LX2-32c causes G2/M phase cell cycle arrest and induces apoptosis in cancer cells. It has demonstrated antitumor effects in models of gastric carcinoma, non–small cell lung cancer, breast cancer (including metastatic models), and prostate cancer. This molecule is under investigation in various formulations including cremophor-based and liposome-based delivery and polymeric micelles to improve pharmacokinetics and reduce toxicity, especially hypersensitivity, bone marrow, and cardiac toxicities. Its clinical development is primarily focused on cancer therapy[1][2][3][4][5][6][7].